All News
Happy Diwali (11.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.
Read Article
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Dot the "i", Cross the "t" (10.11.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Today’s reports suggest where to look for help, especially with regard to pain.
Read Article
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.… https://t.co/VREQCx8TfI https://t.co/ylzYPHhedi
Dr. John Cush RheumNow ( View Tweet)
Psoriasis pts w/ Arthralgia referred for Rheum Eval - 1419 referred pts, 8.4% (119) met at risk for PsA criteria, and 29% (35) developed PsA w/in 1yr. Predictors included +FHx PsO, Ultrasound synovitis or enthesopathy findings, & low tender joint count. https://t.co/Fxgiu6D72j https://t.co/b8dMCOC18F
Dr. John Cush RheumNow ( View Tweet)
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/INcke6eLLC https://t.co/TGyxzmCrjv
Dr. John Cush RheumNow ( View Tweet)
Real-world study of 76 #PsA pts (Dz Duration Psoriasis 216 mos, PsA 120 mos. No correlatons seen between skin/PASI scores and PsA clinical variables, except the signif correlation betw PASI & enthesitis (ρ = 0.285; p = 0.013). https://t.co/K6FXjE5A4N https://t.co/NVlPiPVT0s
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today!
https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw
Links:
Dr. John Cush RheumNow ( View Tweet)
In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar. https://t.co/QVbEVvYz7y https://t.co/1Te22NIUGT
Dr. John Cush RheumNow ( View Tweet)
Manual labor jobs have more work disability in #PsA. 564 PsA pts, 29% were Blue collar; 71% White Collar. BCol (80% male) had more work disability at baseline (84% vs 28%; p < 0.01). Occupation did not influence DAS28-CRP remission at 1 yr, suggesting Rx response unaffected by… https://t.co/A9E5WZqIwu https://t.co/8PelrtpXco
Dr. John Cush RheumNow ( View Tweet)
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK
Dr. John Cush RheumNow ( View Tweet)
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX.
Join the Revolution in Rheumatology Education!
https://t.co/ygjZRMVkOZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Screening to Prevent Multimorbidity in Rheumatic Patients
A population based screening program of patients with chronic inflammatory rheumatic diseases (IRD) demonstrates that systematic screening IRD patients for multimorbidity increased preventive interventions and reduced… https://t.co/qh0mkN8HgD https://t.co/ggz5bafCMt
Dr. John Cush RheumNow ( View Tweet)
Comparison of 2 criteria for "difficult to Rx PsA" - 378 pts - 19.8% met Perrotta criteria, & 15.3% met Kumthekar D2T criteria. Sensitivity 30-38%, but specificity 82- 86%, w/ good agreement betw 2 sets. D2T-PsA research is needed! https://t.co/MUWPsargrU https://t.co/P40DAkb5qT
Dr. John Cush RheumNow ( View Tweet)
Cytokines/biomarkers from IL-23/IL-17 pathways are Increased in psoriasis. Subanalysis of phase 2 254 pt PsO trial revealed that 12 wks of deucravacitinib assoc w/ reduction in IL-17A, IL-17C, beta-defensin, PI3 - decreases correlated w/ PASI changes https://t.co/Ii381B2mZx https://t.co/vXDyLUsKPi
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a 4th biosimilar to Stelara - the new agent, ustekinumab-srl (Imuldosa), is indicated for Rx of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Originator Stelara sales in 2023 were nearly $10.86 USD billion globally… https://t.co/MoNBj2UaVH https://t.co/3Tenkfq0KK
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib safety across in RA, PsA, AS, atopic dermatitis >15000 Pt-Yrs exposure. Rates (per 100PYs) of Hzoster (1.6–3.6), NMSC (0–0.8) & incr CPK (4.4–7.9) higher w/ UPA vs comparators (RA, PsA); Deaths (0–0.8), SIE (0–3.9), MACE (0–0.4), VTE (<0.1–0.4), CA, malignancies… https://t.co/OoJ5OX7JyL https://t.co/vaMVFmldEB
Dr. John Cush RheumNow ( View Tweet)
World renowned faculty delivering state of the art lectures. Early bird registration for RheumNow Live is now open!
https://t.co/Yk8dKDdZie https://t.co/d14Mq2AxlI
Links:
Dr. John Cush RheumNow ( View Tweet)
